IDEXX Cancer Dx testing

Resources

Learn more about veterinary oncology.

Access a curated collection of education at the IDEXX Learning Centre, including webinars, news, links to industry resources and more.

Visit now

Get Started in Oncology: 4 Self-Paced Courses

Canine Cancer Screening

Making Sense of the Why, the When, and the Next Steps

60 min

Let’s Make Cancer History

Introducing IDEXX Cancer Dx Testing

10 min

Confidence in Cancer Care

Practical Approaches to Canine Lymphoma Diagnosis and Staging

10 min

Confidence in Cancer Care

Practical Approaches to Lymphoma Diagnosis and Management

60 min

Downloadable medical resources.

Having the medical materials at hand makes it easy for your practice to have the information you need, when you need it. Here, you’ll find links to the IDEXX Cancer Dx testing white paper, algorithm and case study.

Clinical reference guide

An easy, convenient way to learn about cancer prevalence, risk factors, how to use IDEXX Cancer Dx testing and more.

White paper

Access the data and details on IDEXX Cancer Dx testing.

Algorithm

Everything you need to know to get started and up to speed on IDEXX Cancer Dx testing.

Case study

Read this case study on Sophie, a 5-year-old golden retriever whose IDEXX Cancer Dx testing results were consistent with lymphoma.

Lymphoma resources on The Vetiverse

Lymphoma in Dogs 101: A Guide for Veterinarians

From Breed to Environment: Key Risk Factors for Canine Cancer

How to Talk to Pet Owners About Cancer Including Top Questions to Answer

Dog Breeds and Cancer: Which Dogs Have Increased Risk?

How to Distinguish B-Cell Lymphoma from T-Cell Lymphoma in Dogs

FAQs

IDEXX Cancer Dx testing provides accurate detection of biomarkers specific for lymphoma in canine serum and whole blood. B-cell vs. T-cell phenotype classification will be provided with positive results as available at no additional cost.

IDEXX Cancer Dx testing provides three indications, both for canine lymphoma:

  • Aid in diagnosis: IDEXX Cancer Dx testing can be performed on dogs in which lymphoma is suspected, whether that be due to a physical examination abnormality, blood work abnormality, report of illness or change in behaviour at home.
  • Screening: In early studies, IDEXX Cancer Dx testing has the potential to detect lymphoma up to 6–8 months in advance of the onset of clinical signs.¹ This would be most appropriately used in senior dogs (aged 7 years and older) and at-risk breeds aged 4 and older.
  • Monitoring: In patients with a positive IDEXX Cancer Dx testing result at diagnosis (pretreatment), repeated testing can be used to monitor remission during CHOP chemotherapy.

At-risk dogs include dogs of all breeds aged 7 or older and dogs of breeds at increased risk for cancer aged 4 or older. These dog breeds have an increased risk for lymphoma: Labrador retriever, rottweiler, Doberman pinscher and English bulldog. Dog breeds at increased risk for cancer include those above along with these: golden retriever, French bulldog, beagle, boxer, miniature schnauzer, Bernese mountain dog, flat-coated retriever, Scottish terrier and bullmastiff.

The specimen requirement for IDEXX Cancer Dx testing is 1 mL of EDTA whole blood and 2 mL of serum when run as a standalone. When run in or with a profile that includes chemistry and CBC, IDEXX Cancer Dx testing is run using a portion of the submitted specimen, which should be at least 1 mL whole blood/2 mL serum (or any further profile requirement). When submitted with a profile request, a separate pair of tubes is NOT required for IDEXX Cancer Dx testing.

Results will be reported as either ‘consistent with lymphoma’ or ‘not consistent with lymphoma’. If a result is unable to be obtained on the specimen submitted, the customer will be notified appropriately within their results view.

References

  1. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: Data based on testing performed at IDEXX Reference Laboratories in North America between November 1, 2024, and December 6, 2024. Analysis Report: IDEXX Cancer Dx Validation, 100282 [008_CancerDx-Validation-Report-2.Rmd].